Genicular Artery Embolisation for Knee Osteoarthritis II

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45+
SponsorVarian, a Siemens Healthineers Company

About this trial

This clinical study is designed as a double-blind sham controlled randomised trial with the option of sham group crossover to receive the GAE treatment at 6 months after unblinding. This study will determine if embolisation of abnormal neovasculature arising from branches of the genicular arteries reduces pain in patients with knee osteoarthritis. The study patient population will consist of up to 110 subjects with knee pain for at least 3 months that is resistant to conservative treatment measures. Subjects will be treated with knee embolisation or 2 mL of saline in the sham arm. At 6 months, all subjects in the sham arm will be allowed to cross-over and receive the embolisation procedure with a follow-up duration of 18 months. The total planned study duration is 3.5 years.

Eligibility criteria

Qualifiers

Participant is willing and able to give informed consent for participation in the study.

Participants aged 45 years or above.

Grade 1-3 knee OA on X-ray as per Kellgren-Lawrence Grading Scale

Knee pain for at least 3 months resistant to conservative non-surgical treatment (e.g., physiotherapy, steroid injections, weight loss programs, PRP (platelet-rich plasma) injections)

Disqualifiers

Rheumatoid arthritis or infectious arthritis

Severe knee OA (grade 4 on x-ray as per Kellgren-Lawrence Grade)

Renal impairment: eGFR <45. Assessed from medical records or a blood test if required as is part of standard clinical practice when considering a patient for a therapeutic intervention.

Patients with a bleeding diathesis, or other bleeding risk such as patients on warfarin which cannot be stopped easily (e.g., patients with metallic heart valves) assessed by asking the patient and from medical records. Uncorrectable bleeding diathesis: INR>1.6, Platelets <50,000

Trial design

Treatments tested in this trial

  • Genicular Artery Embolisation
  • Genicular Artery Injection

Treatment groups

110 Participants
are divided into 2 treatment groups